Table 4 Outcomes after transplantation in patients with VAD and without VAD

Patients with ≥1 post transplant bacterial/candida infection episode, n (%)

39 (46.4)

12 (34.3)

Number of episodes of bacterial/candida infections per patient; mean (SD)

0.83 (1.31)

0.51 (0.82)

Number of post-transplant bacterial/candida infections episodes

70

18

Sites of bacterial/candida infections; n (%)^a

 - Respiratory tract

 - Bacteremia

 - Urinary tract

 - Surgical site

 - Other^b

18 (25.7)

11 (15.7)

12 (17.1)

17 (24.3)

17 (24.3)

4 (22.2)

5 (27.7)

3 (16.7)

7 (38.9)

2 (11.1)

Microorganisms; n (%)

 - Escherichia coli

 - Coagulase Negative Staphylococci

 - Staphylococcus aureus

 - Pseudomonas sp.

 - Clostridium difficile

 - Enterobacter sp.

 - Candida sp.

 - Polymicrobial

 - Other

10 (14.3)

6 (8.6)

6 (8.6)

6 (8.6)

5 (7.1)

6 (8.6)

6 (8.6)

5 (7.1)

19 (27.1)

2 (11.1)

1 (5.6)

1 (5.6)

0

2 (11.1)

2 (11.1)

1 (5.6)

3 (16.7)

7 (38.9)

Viral infections

 - CMV infection

 - VZV infection

 - HSV infection

31 (36.9)

8 (9.5)

15 (17.9)

8 (22.9)

3 (8.6)

1 (2.9)

Other fungal infections

 - Aspergillus spp.infection

 - Pneumocystis jiroveci pneumonia

7 (8.3)

3 (3.6)

1 (2.9)

0 (0.0)

Length of stay after transplant, days; mean (SD)

60.8 (65.0)

82.9 (127.6)

Patients with treated acute rejection, n (%)

57 (67.9)

22 (62.9)

Survival; n (%)

69 (82.1)

29 (82.9)